AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

It is a sign of its frustration felt within Britain's largest company that it has chosen to publicly contrast the new government with the last. Image: Rachel Reeves. Pic: PA AstraZeneca draws just ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The company’s shares opened today at p11,242.00.

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price target of p13,100.00. The company’s shares opened ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

The institutional investor owned 10,908 shares of the company’s stock after selling 674 shares during the quarter. Mutual Advisors LLC’s holdings in AstraZeneca were worth $730,000 at the end ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on ... The newspaper said Reeves wanted to reduce state provisions to the company's vaccine centre, which would cut the pledge made ...

AstraZeneca, which produced one of the Covid-19 jabs, has an existing site on Renaissance Way, Speke and during the spring budget in March 2024, then-Chancellor Jeremy Hunt confirmed the company ...

One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, AstraZeneca currently ...

Looking ahead, how do you see AstraZeneca’s advancements in ATTR-CM and the broader CVRM field shaping the future of patient care, especially as the company continues to focus on innovative ...